期刊文献+

幼年特发性关节炎全身型反复发作患儿临床特点及治疗探讨 被引量:4

The exploration of the clinical features and treatments of children’s recurrent systemic onset juvenile idiopathic arthritis
暂未订购
导出
摘要 目的探讨幼年特发性关节炎全身型(SOJIA)反复发作的临床特点及治疗方法。方法回顾性分析27例SOJIA的临床资料,将27例sOJIA分为2组,无反复发作者为A组,反复发作者为B组,以激素和甲氨喋呤(MTX)联合治疗作为基本方案。随访1年以上。结果治疗前,B组患儿的浆膜腔积液发生率(100%)明显高于A组(33.3%),差异有统计学意义(P〈0.05)。治疗前和治疗3周时,B组患儿的外周血IgM、铁蛋白(SF)、NT-proBNT、CK水平均高于A组,差异均有统计学意义(f=2.83-7.23,P均〈O.05)。两组患)LMTX应用率和遵照激素联合MTX治疗的减量、停药原则的人数比例A组均高于B组,差异有统计学意义(P〈O.05)。结论浆膜腔积液,血液IgM、SF、NT-proBNT、CK水平异常升高,单用激素治疗,联合用药疗程不足可能是SOJIA反复发作的原因。 Objective To investigate the clinical features and treatments of children's recurrent systemic onset juvenile idiopathic arthritis (SOJIA). Methods To retrospective analysis of the clinical data of 27 cases of children with SOJIA, which were divided into two groups. The non-recurrent SOJIA children were referred to as A group, and the recurrent SOJIA chil- dren were referred to as B group. The therapy of hormones in combination with methotrexate (MTX) was as the basic program. Follow up of A and B group more than 1 year. Results Before treatment, the incidence of serous effusion B group (100%) was significantly higher than A group (33.3%), the difference of the two groups was statistically significant (P〈0.05). Before treat- ment and after 3 weeks treatment, among the laboratory parameters of IgM, SF, NT-pro BNT, CK of A, B groups were statisti- cally significant (P〈0.05); the difference orb groups were significantly higher than A group (t=2.83-7.23, AIIP〈0.05). The ap- plication rate of MTX, the proportion of following of the principle of the withdrawal and reduction of hormones and MTX were statistically significant (BothP〈0.05). Conclusions Serous effusion, the high levels of IgM, SF, NT-proBNT、 CK of peripheral blood, use of hormones alone, and too short treatment of combation drugs may be the reason of the recurrent attacks of SOJIA.
出处 《临床儿科杂志》 CAS CSCD 北大核心 2012年第12期1128-1131,共4页 Journal of Clinical Pediatrics
关键词 全身型幼年特发性关节炎 临床特点 治疗 疗效 systemic onset juvenile idiopathic arthritis clinical features treatment clinical efficacy
  • 相关文献

参考文献16

  • 1宋红梅.幼年特发性关节炎的诊断[J].临床儿科杂志,2011,29(1):18-21. 被引量:27
  • 2Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis., second revision, Edmonton, 2001 [J]. J Rheumatol, 2004, 31(2): 390-392.
  • 3Yokota S, Mori M, Imagawa T, et al. Proposal for juvenile idiopathic arthritis guidance on diagnosis and treatment for primary care pediatricians and nonpediatric rheumatolo- gists (2007) [J]. Mod Rheumatol, 2007, 17(5): 353-363.
  • 4Wallace CA, Ruperto N, Giannini E, et al. Preliminary criteria for clinical remission for select categories of juve- nile idiopathic arthritis [J]. J Rheumatol, 2004, 31(11).. 2290-2294.
  • 5王淑兰,安东,杨志亮,姜红,罗钢.幼年特发性关节炎诊断分析及治疗新进展[J].中国实用儿科杂志,2005,20(10):579-584. 被引量:8
  • 6Sulli A, Montecucco CM, Caporali R, et al. Glucocorticoid effects on adrenal steroids and cytokine responsiveness in polymyalgia rheumatica and elderly onset rheumatoid arthritis [J]. Ann N Y Acad Sci, 2006, 1069: 307-314.
  • 7Buttgereit F, Burmester G, Bijlsma JW. Which dose regi- men for glucocorticoid pulse therapy in patients with severe refractory RA? [J]. Ann Rheum Dis, 2005, 64(1): 171-172.
  • 8Makrygiannakis D, af Klint E, Catrina SB, et al. Intraar- titular corticosteroids decrease synovial RANKL expres- sion in inflammatory arthritis [J]. Arthritis Rheum, 2006, 54(5): 1463-1472.
  • 9薛海燕,曹兰芳,马敏,卢燕鸣,毛海英,顾越英.激素治疗难治性全身型幼年特发性关节炎39例[J].实用儿科临床杂志,2007,22(9):678-679. 被引量:4
  • 10Smolen JS, Landewe R, Breedveld FC, et al. EULAR recom- mendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheu- matic drugs [J]. Ann Rheum Dis, 2010, 69(6): 964-775.

二级参考文献84

  • 1邱力军,彭图元.检测窒息新生儿血浆D-二聚体的临床意义[J].新医学,2004,35(12):741-742. 被引量:3
  • 2闵月,徐琴英,王丽峰,宋晓翔,倪征,程江,封其华,李晓忠.全身型幼年特发性关节炎40例[J].实用儿科临床杂志,2005,20(11):1082-1084. 被引量:4
  • 3谭永强,曹兰芳,毛海英,卢燕鸣,夏敏,李亚琴.幼年型特发性关节炎患儿血D-二聚体测定的临床意义[J].临床儿科杂志,2006,24(4):299-302. 被引量:4
  • 4施桂英.肿瘤坏死因子-α抑制剂诱发银屑病[J].药物不良反应杂志,2007,9(2):103-105. 被引量:3
  • 5鲁珊,周薇,张倩,于新颖,刘东明,刘湘源.幼年银屑病关节炎[J].中国当代儿科杂志,2007,9(4):339-342. 被引量:3
  • 6Petty RE,Southwood TR,Manners P,et al.International League of Associations for Rheumatology classification of juvenile idiopathic arthritis:second revision,Edmonton,2001[J].J Rheumatol,2004,31(2):390-392.
  • 7Dannecker GE,Quartier P.Juvenile idiopathic arthritis:classification,clinical presentation and current treatments[J].Horm Res,2009,72(Suppl 1):4-12.
  • 8Ravelli A,Felici E,Magni-Manzoni S,et al.Patients with antinuclear antibody-positive juvenile idiopathic arthritis constitute a homogeneous subgroup irrespective of the course of joint disease[J].Arthritis Rheum,2005,52 (3):826-832.
  • 9Kuemmerle-Deschner JB,Horneff G.Safety and efficacy of once-weekly application of etanercept in children with juvenile idiopathic arthritis[J].Rheumatol Int,2007,28(2):153-156.
  • 10Horneff G,Ebert A,Fitter S,et al.Safety and efficacy of once weekly etanercept 0.8 mg/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis[J].Rheumatology (Oxford),2009,48(8):916-919.

共引文献50

同被引文献56

  • 1周纬,殷蕾,金燕樑,杨珍.非甾体类消炎药联合甲氨蝶呤治疗全身型幼年特发性关节炎疗效观察[J].临床儿科杂志,2006,24(8):663-665. 被引量:4
  • 2Beukelman T, Patkar N M, Saag K G, et al, 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features[J]. Arthritis Care Res (Hoboken), 2011,63(4): 465-482.
  • 3Verma P, Dalai K. Serum cartilage oligomeric matrix protein (COMP) in knee osteoarthritis: a novel diagnostic and prognostic biomarker[J]. J Orthop Res, 2013, 31(7): 999-1006.
  • 4Andersson M L, Svensson B, Petersson I F, et al. Early increase in serum-COMP is associated with joint damage progression over the first five years in patients with rheumatoid arthritis[J], BMC Musculoskelet Disord. 2013.14: 229.
  • 5Stinson J N, Luca N J, Jibb L A. Assessment and management of pain in juvenile idiopathic arthritis[J]. Pain Res Manag, 2012,17(6): 391-396.
  • 6Laurell L, Court-Payen M, Boesen M, et al. Imaging in juvenile id- iopathic arthritis with a focus on ultrasonography[J]. Clin Exp Rheumatol, 2013, 31(1): 135-148.
  • 7Bender A L, da Silveira I G, von Muhlen C A, et al. High specificity but low sensitivity of the cartilage oligomeric matrix protein (COMP) test in rheumatoid arthritis and osteoarthritis[J]. Clin Chem Lab Med, 2010, 48(4): 569-570.
  • 8Happonen K E, Saxne T, Aspberg A, et al. Regulation of comple- ment by cartilage oligomeric matrix protein allows for a novel molecular diagnostic principle in rheumatoid arthritis[J]. Arthritis Rheum, 2010,62(12): 3574-3583.
  • 9Christensen A F, Lindegaard H, Horslev-Petersen K, et al.Carti- lage oligomeric matrix protein associates differentially with ero- sions and synovitis and has a different temporal course in cyclic citrullinated peptide antibody (anti-CCP)-positive versus an- ti-CCP-negative early rheumatoid arthritis[J]. J Rheumatol, 2011,38(8): 1563-1568.
  • 10Bjornhart B, Juul A, Nielsen S, et al.Cartilage oligomeric matrix protein in patients with juvenile idiopathic arthritis: relation to growth and disease activity[J]. J Rheumatol, 2009, 36(8): 1749- 1754.

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部